Respiratory Drugs Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with ...

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...

Patients with chronic obstructive pulmonary disease (COPD) have multiple breathing problems and, at the more severe stages, experience acute exacerbations of COPD up to three times annually. Because ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. According to a new study published in the Annals of ...

In keeping with the new trend for providing "living guidelines," the Global Initiative for Asthma (GINA) Scientific Committee released their latest update a few months ago. The push toward earlier ...

Please provide your email address to receive an email when new articles are posted on . Doubling the inhaled corticosteroid dose and adding umeclidinium to inhaled ...

A study published by the New England Journal of Medicine (NEJM) of the head-to-head FLAME study [The study was funded by Novartis Pharmaceuticals], compared the ...

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies. Jeffrey D. Dunn, PharmD, MBA: ICSs [inhaled corticosteroids] haven’t shown much evidence in impacting the course of ...

LABA/LAMA is associated with a similar or lower risk of cardiovascular and cerebrovascular adverse events compared to treatment with LABA/inhaled corticosteroid. According to a new study published in ...